NASDAQ:FGEN - FibroGen Stock Price, Forecast & News

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen Inc (NASDAQ:FGEN) released its quarterly earnings results on Monday, November, 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.02. The biopharmaceutical company had revenue of $33.17 million for the quarter, compared to analysts' expectations of $31.61 million. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. The firm's revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.50) earnings per share. View FibroGen's Earnings History.

FibroGen is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for FibroGen.

5 brokerages have issued 1 year target prices for FibroGen's shares. Their forecasts range from $40.00 to $72.00. On average, they anticipate FibroGen's stock price to reach $57.00 in the next year. This suggests a possible upside of 31.8% from the stock's current price. View Analyst Price Targets for FibroGen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.

News stories about FGEN stock have trended somewhat positive recently, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. FibroGen earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for FibroGen.

Some companies that are related to FibroGen include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Transocean (RIG).

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.32%), Assenagon Asset Management S.A. (0.08%), Woodstock Corp (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Nisa Investment Advisors LLC. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo and Thomas B Neff. View Insider Buying and Selling for FibroGen.

FGEN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Woodstock Corp and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $43.25.

FibroGen has a market capitalization of $3.77 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. FibroGen employs 461 workers across the globe.View Additional Information About FibroGen.

The official website for FibroGen is http://www.fibrogen.com/.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]